Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  veliparib
Find trials that include:  Any drugs shown
Results 1-25 of 26 for your search:
Start Over
Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme
Status: Temporarily closed
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A071102, NCI-2014-00616, CALGB-A071102, NCT02152982
Veliparib and Topotecan Hydrochloride in Treating Patients with Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8329, NCI-2011-00312, 09-000742, CDR0000657976, MAYO-MC0861, MC0861, NCT01012817
Veliparib with or without Radiation Therapy, Carboplatin, and Paclitaxel in Patients with Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8811, NCI-2011-02592, CDR0000701003, CHNMC-PHII-111, PHII-111, S1206, NCT01386385
Veliparib and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2009-608, NCI-2013-00656, NCT01489865
Combination Chemotherapy with or without Veliparib in Treating Patients with Stage IV Head and Neck Cancer
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: A091101, NCI-2012-02009, NCT01711541
I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 097517, NCI-2015-00014, NCT01042379
Gemcitabine Hydrochloride and Cisplatin with or without Veliparib or Veliparib Alone in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8993, NCI-2012-00864, CDR0000732189, IRB#12-045, MSKCC-12-045, 12-045, NCT01585805
Molecular Profiling-Based Targeted Therapy in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9149, NCI-2013-01588, 130105, MPACT, P121047, NCT01827384
Cisplatin with or without Veliparib in Treating Patients with Stage IV Triple-Negative and/or BRCA Mutation-Associated Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1416, NCI-2015-01912, NCT02595905
Veliparib and Atezolizumab Either Alone or in Combination in Treating Patients with Stage III-IV Triple Negative Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10020, NCI-2016-01130, NCT02849496
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients with Metastatic Pancreatic Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1513, NCI-2015-02248, NCT02890355
Veliparib and Combination Chemotherapy in Treating Patient with Locally Advanced Rectal Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NRG-GI002, NCI-2016-00222, NCT02921256
Veliparib and Irinotecan Hydrochloride in Treating Patients with Cancer That Is Metastatic or Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: 7977, NCI-2009-01057, 2007-014, CDR0000579642, HIC1410014852, WSU-2007-014, NCT00576654
Veliparib, Paclitaxel, and Carboplatin in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8808, NCI-2011-02500, CDR0000700997, UPCI 10-115, NCT01366144
Veliparib and Dinaciclib in Treating Patients with Advanced Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 8484, NCI-2011-03458, 11-144, CDR0000710900, DFCI-11-144, NCT01434316
Veliparib and Radiation Therapy before Surgery in Treating Patients with Stage IIB-IV Breast Cancer with Incomplete Response to Chemotherapy
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11155, NCI-2012-02760, CIR00006912, NA_00048362, NCT01618357
Veliparib and Floxuridine in Treating Patients with Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1114, NCI-2012-02767, 9182, NCT01749397
Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: M14-361, NCI-2015-00490, 2014-001764-35, NCT02289690
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Temporarily closed
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, TBD, NCT02631733
Veliparib, ATR Kinase Inhibitor VX-970, and Cisplatin in Treating Patients with Refractory Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9771, NCI-2016-00355, P141582, 16-C-0087, NCT02723864
Veliparib, Capecitabine, and Temozolomide in Treating Patients with Advanced, Metastatic, and Recurrent Neuroendocrine Tumor That Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 19 and over
Trial IDs: VICC GI 14134, NCI-2016-01044, NCT02831179
Nivolumab and Veliparib in Treating Patients with Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma with or without Alterations in DNA Repair Genes
Status: Not yet active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: NU 16MH03, NCI-2016-02018, STU00204250, NCT03061188
Start Over